Biomarin Pharmaceutical (BMRN) Income from Continuing Operations (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Income from Continuing Operations data on file, last reported at 105527000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 43.17% year-over-year to 105527000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 268742000.0 (down 48.7% YoY) and the FY2025 annual result came in at 348901000.0, down 18.26% from the prior year.
• Income from Continuing Operations improved to 105527000.0 in Q1 2026, from 46573000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 240532000.0 in Q2 2025 to a low of 46573000.0 in Q4 2025.
• A 5-year average of 70029000.0 and a median of 56040000.0 in 2023 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 8282.73% — and 2025, when it slumped 137.28%.
• Tracing BMRN's Income from Continuing Operations over 5 years: stood at 249000.0 in 2022, then soared by 8282.73% to 20375000.0 in 2023, then jumped by 513.22% to 124943000.0 in 2024, then tumbled by 137.28% to 46573000.0 in 2025, then soared by 326.58% to 105527000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 105527000.0 (Q1 2026), 46573000.0 (Q4 2025), and 30744000.0 (Q3 2025), per Business Quant data.